Difference between revisions of "Partial antagonist-Partial antagonist"
From Psychiatrienet
| Line 5: | Line 5: | ||
| stop = {{StopStand}} | | stop = {{StopStand}} | ||
| start = {{Startpartial}} | | start = {{Startpartial}} | ||
| − | | view = | + | | view = PartialtoPartial.jpg |
}} | }} | ||
Latest revision as of 16:01, 29 October 2021
| ||||
| ||||
Switch medication from Partial antagonist to Partial antagonist.[1]
[2]
Partial antagonist is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'partial antagonist' group from anotherdrug should be read as partial antagonist-anotherdrug. Similarly, a switch from a member of the 'partial antagonist' group to anotherdrug should be read as anotherdrug-partial antagonist.
Stop Partial antagonist - Day 1-4: approx. 75% of initial dose
- Day 5-8: approx. 50% of initial dose
- Day 9-12: approx. 25% of initial dose
- Day 13: stop
Start Partial antagonist- Day 1-3: start 50% of target dose
- Day 4-7: target dose
More information
— Partial antagonist — Partial antagonist
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
